Multiple Sclerosis Clinical Trials in Dallas
View 24 new treatments for Multiple Sclerosis in Dallas, TX, and other areas near me, such as Allen, Arlington, Carrollton, Denton, Frisco, Garland, Grand Prairie, Irving, Lewisville, McKinney and Mesquite. Every day, Power helps hundreds of Multiple Sclerosis patients connect with leading medical research.Frexalimab for Multiple Sclerosis
Sanofi Clinic, Dallas + 2 more
This trial compares a new treatment, frexalimab, with an existing pill, teriflunomide, in adults aged 18-55 who have relapsing multiple sclerosis. The study aims to see if frexalimab can reduce the frequency of symptom relapses better than teriflunomide. Participants will be monitored over several years.Show More
Verified
Ocrelizumab for Multiple Sclerosis
Research Clinic, Dallas + 1 more
This trial is testing if patients with early relapsing multiple sclerosis can stop taking Ocrelizumab after initial treatment without their disease getting worse. Ocrelizumab is a medication given through an IV that helps manage multiple sclerosis by reducing harmful immune cells. The study will monitor patients for new disease activity over several years.Show More
Cladribine for Multiple Sclerosis
Research Clinic, Dallas + 1 more
The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple sclerosis (RMS; to include relapsing-remitting MS \[RRMS\] or active secondary progressive MS).Show More
No Placebo Trial
Ofatumumab for Early Relapsing-Remitting Multiple Sclerosis
Novartis Clinic, Dallas + 2 more
This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes. The study will also assess changes in disease using monitoring techniques including digital biometric device use, biomarker analysis and non-conventional MRI. Select outcomes in the ofatumumab treated group will be compared to a group of Healthy participants to determine if there are similarities between the groups after the patients with MS undergo treatment with ofatumumab.Show More
No Placebo Trial
Cladribine After Natalizumab for Multiple Sclerosis
Research Clinic, Dallas + 1 more
The purpose of this study is to generate hypotheses regarding the safety, efficacy, and immunological impact of cladribine tablets after treatment with natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (active SPMS).Show More
No Placebo Trial
High-Dose Ocrelizumab for Multiple Sclerosis
Hoffmann-La Roche Clinic, Dallas + 1 more
This trial is testing if a higher dose of ocrelizumab given through an IV drip is more effective and safe for patients with Primary Progressive Multiple Sclerosis (PPMS). The drug works by reducing harmful immune cells to potentially slow down the disease. Ocrelizumab is the first drug approved for treating both relapsing and primary progressive forms of multiple sclerosis.Show More
No Placebo Trial
Ozanimod for Multiple Sclerosis
Celgene Clinic, Dallas + 2 more
This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the SDMT, in subjects with RMS treated with ozanimod HCl 1 mg at 3 years. All subjects will receive orally administered ozanimod HCl 1 mg. The primary efficacy endpoint is the proportion of subjects with a clinically meaningful increase in raw score of ≥ 4 points or 10% from baseline (improved). The treatment period is 36 months. For all subjects who finish the subject and for those who discontinue, there will be a 30-day (± 15 days) and a 90-day (± 10 days) Safety Follow-up Visit. There is no planned protocol extension following the end of the study. Approximately 250 subjects with RMS will be recruited for this study. Subjects with RMS will be enrolled in this study if they have received ≤ 1 DMT, have an EDSS ≤ 3.5, and have been diagnosed with RMS within 5 years of study entry. The Investigator will be responsible for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS relapses, and management of AEs.Show More
No Placebo Trial
Ofatumumab for Multiple Sclerosis
Novartis Clinic, Plano + 2 more
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.Show More
No Placebo Trial
Fenebrutinib for Relapsing Multiple Sclerosis
Hoffmann-La Roche Clinic, Plano + 2 more
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.Show More
Ocrelizumab vs Fingolimod for Pediatric Multiple Sclerosis
Hoffmann-La Roche Clinic, Fort Worth + 1 more
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and \< 18 years over a flexible duration. The double-blind period will last until after the last participant randomized has completed 24 weeks.Show More
Frequently Asked Questions
How much do multiple sclerosis clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.
Do I need to be insured to participate in a medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
How do multiple sclerosis clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across multiple sclerosis trials in Dallas, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for multiple sclerosis patients is 6 Months.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.
Where in Dallas is research being conducted for multiple sclerosis?
The University of Texas Southwestern Medical Center in Dallas is conducting multiple sclerosis clinical trials, with approximately 3 trials ongoing. These trials are centered in the southwestern part of the city.
What promising new drugs are being tested?
In Dallas, research for multiple sclerosis includes treatments like Monoclonal Antibodies and Sphingosine-1-Phosphate Receptor Modulators. Notable drugs being studied are Ocrelizumab, Ofatumumab, and Siponimod.